Compare VNRX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | KTTA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.9M |
| IPO Year | 2012 | N/A |
| Metric | VNRX | KTTA |
|---|---|---|
| Price | $2.42 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.67 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.7M | 486.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.28 |
| 52 Week High | $2.89 | $2.06 |
| Indicator | VNRX | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 79.62 | 63.61 |
| Support Level | $0.22 | $0.67 |
| Resistance Level | $2.89 | $0.90 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 82.83 | 60.70 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).